EU approves Bayer's new long-term contraceptive: firm

December 5, 2012

German drug maker Bayer said on Wednesday that European Union authorities had given the go-ahead for a new contraceptive which can prevent pregnancies for up to three years.

Bayer said in a statement that its healthcare division "has successfully concluded the European registration procedure for its new low dose -releasing intrauterine system (IUS)."

IUS is "a long-term placed in the uterus for the prevention of pregnancy for up to three years."

First launches of the product—which will be marketed under the name "Jaydess"—are expected in the second quarter of 2013 in the EU, the statement said.

Bayer also applied for US marketing authorisation for the product in December 2011.

Explore further: Some birth control shows higher clot risk: US

Related Stories

Some birth control shows higher clot risk: US

October 28, 2011

Some birth control products, including contraceptive pills, rings and patches for women, carry a significantly higher risk of blood clot than low-dose medications, US regulators said Thursday.

ACOG: Intrauterine device insertion linked to weight loss

May 7, 2012

(HealthDay) -- Women who undergo postpartum or interval insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) or Copper T 380A (CU-T) intrauterine devices experience weight loss in the two years following insertion, ...

Recommended for you

FDA bolsters warnings about class of antibiotics

July 26, 2016

(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including ...

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.